You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Cognitive Behavioral Therapy for Migraine Headache
Edit
This entry is adapted from the peer-reviewed paper 10.3390/medicina58010044

Migraine headaches are chronic neurological diseases that reduce the quality of life by causing severe headaches and autonomic nervous system dysfunction, such as facial flushing, nasal stuffiness, and sweating. Their major treatment methods include medication and cognitive behavioral therapy (CBT). CBT has been used for pain treatment and various psychogenic neurological diseases by reducing pain, disability, and emotional disorders caused by symptoms of mental illness and improving the understanding of mental health.

migraine migraine headache headache cognitive behavioral therapy

1. Introduction

Migraine is a disease characterized by severe headache accompanied by symptoms, such as nausea, photophobia, phonophobia, and vomiting [1]. The prevalence of migraine is estimated to be 15–18% [2], and it is two to three times higher in women than in men [3][4]. Migraine is a chronic neurological disorder and autonomic nervous system dysfunction that affects patients’ quality of life [5][6]. The preferred treatment for migraine is medication administration. Acute medications include paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), and triptans [7]. Routine use of opioids and barbiturates is not preferred because of their poor safety and tolerability [8][9][10].
Overuse of painkillers can lead to a variety of side effects and medication overuse headache; therefore, attention should be paid to drug abuse during migraine symptoms [11][12]. Non-drug therapy is known to have fewer side effects and can be used simultaneously with medications [12][13].
Physicians who treat migraines are increasingly interested in complementary treatments [14][15]. Medications, such as antidepressants, hypertension treatments, and flunarizine, were common treatment for migraines. However, acupuncture and biobehavial therapy are also used to prevent migraine headaches for patients with little response to existing drug treatment or pregnant women, or patients with psychological disorders. [7][16]. Nutritional supplements, such as riboflavin, pyridoxine, folate, cobalamin, and vitamin D, have recently been widely used as preventive treatments for migraine [17][18][19].
Cognitive behavioral therapy (CBT) is a treatment that uses cognitive factors to improve mental disorders and psychological distress [20]. The latest practice guidelines emphasize CBT as a selective psychotherapy for problems ranging from depression, anxiety, and personality disorders to chronic pain, addiction, and relationship pain [21]. Previous studies have demonstrated the effectiveness of behavioral therapy for migraine headaches, including CBT, relaxation, and biological feedback, to reduce the frequency of migraine attacks and migraine-related disorders [22][23][24].

2. Cognitive Behavioral Therapy for Migraine Headache

Migraine headache is a chronic neurological disease that varies in its frequency and severity, and [25] is a prevalent condition that can severely affect personal, social, and work life during attacks [26][27]. Although the standard treatment for migraine headaches is currently taking medication, a psychiatric approach with a high level of psychological co-prosperity has also recently drawn attention [28][27]. Individuals with migraine are increasingly approaching complementary and integrative health strategies [14][15]. Because patients have an increased preference for CBT treatment for a variety of reasons, several behavioral treatments for migraine prevention have been used, especially during pregnancy or when pharmacological choices for patients are limited, such as low efficacy or lack of durability in pharmacotherapy, or in combination with pharmacological treatments [16].

CBT refers to cognitive processes related to the development and maintenance of psychopathology, particularly emotional pain and dysfunction, which are primarily conducted during sessions, requiring therapists to coordinate interventions to best help patients [29]. CBT therapy enables patients to develop preventive and acute care strategies, such as trigger identification, modification of maladaptive interrelated thoughts, feelings and behaviors surrounding headache, and physiological autoregulation strategies. Behavioral therapies for migraine headaches, including cognitive behavioral therapy, relaxation, and biofeedback, have demonstrated efficacy in reducing migraine attack frequency and migraine-related disorders [22][23][30][31].
Several previous studies have shown that CBT reduces disability and chronic pain in patients [32][33]. CBT had a significant effect on reducing headache frequency and MIDAS scores, which is consistent with the results of previous studies. Therefore, although many studies with more samples are needed in the future, it is believed that CBT can be considered for its use as a complementary therapy for migraine treatment (Table 1).
Table 1. Summary of the results and adverse effects.
Table
Study ID Main Result Baseline (BL) Post-Treatment (PT) Follow-Up (F/U) p-Value Adverse Effect Conclusion
Intervention (Mean ± SD)
Control (Mean ± SD)
Powers
[25]
(2013)		           Group MD in change score at PT I:90
C:109		 ○ In I group, headache days and PedMIDAS decreased significantly compared with control group.
○ Headache days were ≥50% Reduction in 66% of I and 36% of C at PT (odds ratio, 3.5 [95%CI, 1.7 to 7.2]; p < 0.001).
○ PedMIDAS <20 points were in 75% of I, and 56% of C at PT (odds ratio, 2.4 [95%CI, 1.1 to 5.1]; p = 0.02).
HA frequency
(day/month)		 I 21.3 ± 5.2 9.8 ± 9.8 Not mentioned p = 0.002
C 21.3 ± 5.2 14.5 ± 9.8
PedMIDAS I 68.2 ± 31.7 15.5 ± 17.4 Not mentioned 14.1 (95% CI 3.3, 24.9) p = 0.01
C 68.2 ± 31.7 29.6 ± 42.2
Seng
[24]
(2019)		         4 M   ○ No AE in control group
○ 2 AE in intervention group
(1) Vivid recollection of traumatic event while practicing mindfulness
(2) Severe increase in Headache frequency and pain intensity		 ○ HDI change: the group*month interaction was significant, p = 0.004
○ MIDAS: Group*month (N.S. accounting for divided alpha) p = 0.027
○ MIDI: −0.6/10(I), +0.3/10(C) p = 0.007
○ Headache days, headache intensity: Group*month interaction and group*time interaction (N.S.)
HDI 1 I 52.5 ± 21.2   38.2 ± 16.6 p < 0.004
C 50.2 ± 16.2   50.4 ± 14.3
MIDAS 2 Group*month interaction
BL vs. 4 M		 B = 1.6, 95%CI = −0.7,3.9 F(3,213) = 3.12, p = 0.027
MIDAS-A 3 B = 6.3, 95%CI = −2.0,14.5, F(3,94.6) = 1.21, p = 0.312
MIDAS-B 4 B = 0.3, 95%CI = −0.4,1.1, F(3,102.9) = 0.65, p = 0.589
HA days/month I 16.5 ± 6.0   14.8 ± 4.8 p = 0.773    
C 15.5 ± 5.9   14.2 ± 4.8
Average Attack Intensity /month 5 I 1.7 ± 0.3   1.6 ± 0.3 p = 0.888
C 1.8 ± 0.3   1.7 ± 0.3
Average MIDI/month 6 I 2.8 ± 1.6   1.7 ± 2.7 p = 0.007
C 3.4 ± 2.0   4.4 ± 1.3
Grazzi
[26]
(2019)		         3 M   N ○ Headache days and medication intake days declined in I group, not in C group
HA days/month I 10 ± 2.0   6.5 ± 3.5 N
C 9.27 ± 3.43   11.5 ± 4.71
Using medication days/month I 9.4 ± 2.75   5.75 ± 3.3 N
C 9.9 ± 3.6   10.5 ± 5.8
Mansourishad
[27]
(2017)		       3 M   N ○ Covariance analysis showed I group is effective compared with C group in reducing headache frequency (p= 0.001< 0.05), duration (p = 0.001 < 0.05), and severity (p= 0.001 < 0.05) in women with migraine.
HA Frequency (days/month) I 10.63 ± 6.16 4.27 ± 3.01 4.73 ± 2.01 p = 0.001
C 10.81 ± 4.56 10.27 ± 3.21 10.45 ± 6.07
HA Intensity I 6.20 ± 2.30 4.12 ± 1.90 4.32 ± 1.13 p = 0.001
C 6.41 ± 3.40 6.40 ± 2.83 6.50 ± 2.75
HA Duration (h/month) I 10.63 ± 3.05 5.90 ± 4.29 5.08 ± 2.76 p = 0.001
C 11.73 ± 5.49 12.45 ± 6.22 11.36 ± 4.85
            PT F/U    
Smitherman
[34]
(2016)		 HA Frequency
(days/month)		 I 22.7 16.6 11.6 p = 0.883 p = 0.028 N ○ Headache frequency reduction from baseline of I group was not statistically significant com-pared with C group at PT, FU p = 0.883
○ I and C group showed clinically meaningful re-ductions in MIDAS, HIT-6, headache severity at PT, FU with no group differences when controlling for baseline scores
○ No significant group difference in Headache frequency, HIT-6, MIDAS score, headache severity, ESS, PHQ-9, GAD-7, CEQ
○ Significant group difference in TST, sleep efficiency, PSQI
C 19.6 12.5 14.7
MIDAS I 59.9 ± 39.0 44.2 ± 43.1 31.9 ± 33.2 N
C 54.5 ± 41.0 41.0 ± 46.2 34.7 ± 34.5
HIT-6 I 66.9 ± 3.8 62.6 ± 5.3 59.9 ± 5.5 N
C 64.8 ± 3.9 61.4 ± 8.0 59.6 ± 7.2
HA Severity I 5.2 ± 0.9 5.1 ± 1.4 4.5 ± 1.5 N
C 5.4 ± 1.6 5.2 ± 2.1 5.1 ± 1.9
PSQI 7 I 11.3 ± 4.4 7.6 ± 2.6 7.0 ± 3.1 p = 0.009
C 11.6 ± 2.5 10.9 ± 3.8 11.5 ± 3.9
ESS 8 I 11.0 ± 3.4 9.0 ± 3.2 8.9 ± 3.55 N
C 9.9 ± 4.892 9.2 ± 4.7 8.8 ± 4.6
TST (h) 9 I 7.4 ± 1.5 7.3 ± 1.4 8.3 ± 2.6 p = 0.049
C 6.7 ± 1.5 6.9 ± 1.2 6.8 ± 0.5
Sleep Efficiency I 81.2 ± 7.7 79.1 ± 8.9 84.9 ± 4.5 p = 0.001
C 81.2 ± 8.3 82.4 ± 6.4 80.9 ± 4.9
PHQ-9 10 I 12.1 ± 5.8 6.9 ± 4.8 6.3 ± 4.6 p = 0.054
C 10.5 ± 4.5 8.4 ± 4.7 8.6 ± 4.7
GAD-7 11 I 10.6 ± 6.4 6.6 ± 5.2 6.3 ± 4.8 p = 0.430
C 9.8 ± 5.3 7.0 ± 4.6 6.9 ± 4.9
Cousins
[35]
(2015)		         4 M   N ○ At 4 months after treatment, no significant change between I and C group statistically in.
- Diary headache days
- Medication days/ month
- MIDAS, HIT-6, HADS-A,
- HADS-D, IPQ
HA days/month I 12.03 ± 8.70   9 ± 7.27 N
C 11.54 ± 6.64   9.68 ± 6.28
Using rescue medication
days/month		 I 6.69 ± 5.30   5.86 ± 5.12 N
C 7.08 ± 5.87   6.2 ± 4.86
MIDAS I 51.03 ± 43.68   33.86 ± 34.93 N
C 65.78 ± 46.79   53.85 ± 78.49
HIT-6 12 I 66.5 ± 5.88   59.17 ± 8.19 N
C 65.97 ± 4.41   60.85 ± 8.4
HADS-A 13 I 7.78 ± 4.01   5.76 ± 4.45 N
C 9.32 ± 3.55   7.96 ± 4.37
HADS-D I 5.83 ± 4.61   4.24 ± 4.6 N
C 5.68 ± 3.09   4.52 ± 3.51
Brief IPQ 14 I 52.81 ± 9.69   44.17 ± 15.89 N
C 51.41 ± 9.77   45.26 ± 10.17
Wells
[12]
(2014)		           PT FU N ○ The severity and du-ration of all head-aches decreased in the I group, but not statistically significant
○ Significant decrease in I group compared with C group on HIT-6 at PT (p = 0.043), FU(p = 0.022) and MIDAS at PT (p = 0.017)
○ Self-efficacy and mindfulness also in-creased at PT (p = 0.035)
○ MBSR is safe and feasible for adults with migraine.
Migraine Frequency
/month		 I 4.2 ± 2.9 2.6 ± 3.8   p = 0.38 p = 0.63
C 2.9 ± 5.2 2.7 ± 6.9  
HA Frequency
days/month		 I 9.9 * 9.0 * 9.0 * p = 0.14 p = 0.22
C 12.3 * 10.0 * 7.7 *
HA severity (0–10) I 4.4 * 3.2 * 3.3 * p = 0.053 p = 0.66
C 4.8 * 5.2 * 4.8 *
HA duration I 5.1 * 2.9 * 3.6 * p = 0.043 p = 0.19
C 6.4 * 6.1 * 6.1 *
HIT-6 I 63.0 ± 8.0 57.6 ± 6.7 58.3 ± 6.0 p = 0.043 p = 0.022
C 64.7 ± 5.0 64.1 ± 3.8 64.1 ± 3.9
MIDAS I 12.5 ± 9.8 5.9 ± 5.3 5.8 ± 3.8 p = 0.017 p = 0.072
C 11.0 ± 6.7 17.0 ± 11.9 12.0 ± 8.1
HA Management
Self Efficacy		 I 117.2 ± 18.7 122.6 ± 25.0 124.5 ± 22.6 p = 0.035 p = 0.060
C 118.4 ± 31.1 110.7 ± 29.2 111.9 ± 35.7
Five Factor
Mindfulness		 I 142.9 ± 14.7 149.1 ± 18.7 153.8 ± 19.7 p = 0.035 p = 0.045
C 143.7 ± 20.3 136.8 ± 18.3 138.0 ± 19.6
MSQoL 15 I 47.0 * 31.5 * 38.1 * p = 0.12 p = 0.035
C 46.4 * 45.2 * 45.2 *
PHQ-9 16 I 3.6 ± 3.0 2.0 ± 1.8 2.7 ± 2.2 p = 0.77 p = 0.59
C 6.4 ± 6.5 4.2 ± 1.8 3.9 ± 1.9
STAI 17 I 68.7 ± 16.3 61.6 ± 15.0 60.5 ± 16.8 p = 0.13 p = 0.10
C 67.0 ± 15.8 70.2 ± 14.9 69.1 ± 10.3
Perceived Stress Scale-10 I 15.8 ± 6.4 13.3 ± 5.1 12.1 ± 5.1 p = 0.87 p = 0.27
C 14 ± 8.1 12.1 ± 8.0 13.6 ± 7.0
Rapoff
[29]
(2014)		         3 M BL PT N ○ In I group, pain severity decreased at PT compared with C group (p = 0.03)
○ At 3 M FU, significant change in PedMIDAS score in I group compared with C group (p = 0.04)
No other group differences at PT or 3M FU
HA frequency
(% of days)		 I 41.09 ± 22.67 31.28 ± 28.14 21.43 ± 23.47 p = 0.48 p = 0.46 p = 0.36
C 40.67 ± 28.79 32.14 ± 22.23 18.18 ± 17.60
HA duration
(hr/episode)		 I 5.47 ± 4.20 4.47 ± 4.26 1.53 ± 0.91 p = 0.19 p = 0.24 p = 0.07
C 4.15 ± 3.88 5.56 ± 4.01 4.25 ± 5.19
HA severity (VAS) I 5.06 ± 1.84 5.06 ± 1.50 4.46 ± 1.88 p = 0.07 p = 0.03 p = 0.20
C 6.00 ± 1.52 6.25 ± 1.92 3.68 ± 2.04
PedMIDAS total 18 I 13.26 ± 9.69 7.82 ± 10.59 0.91 ± 1.45 p = 0.25 p = 0.14 p = 0.05
C 15.53 ± 10.08 12.29 ± 12.94 3.50 ± 4.86
PedsQL total 19 I 82.10 ± 12.18 83.70 ± 12.07 84.88 ± 18.22 p = 0.25 p = 0.26 p = 0.46
C 79.35 ± 11.55 80.69 ± 14.36 85.67 ± 14.32
Fritsche
[30]
(2010)		         3 M 12–30 M   N ○ Significant change in time effect observed in I, C group in headache days, migraine days, Intake at headache days, Intake at migraine days (p < 0.001)
○ Improvement in psychological variables (p < 0.001)
- Remained stable in both groups at short- and long-term F/U
○ MCT (C) and biblio-therapy (I) are useful to prevent
“medication overuse headache” and transition to chronic head-ache
HA days I 11.40 ± 5.92 9.17 ± 5.45 8.55 ± 5.51 8.68 ± 5.29 Time effect p < 0.001
C 10.51 ± 4.98 8.47 ± 5.54 8.11 ± 4.82 8.33 ± 5.15
Migraine days I 7.23 ± 3.70 5.60 ± 3.79 6.15 ± 3.97 6.15 ± 4.02 Time effect p < 0.001
C 7.27 ± 3.82 5.78 ± 4.01 5.45 ± 3.16 5.84 ± 3.76
HA disability I 4.46 ± 1.80 4.49 ± 2.01 4.61 ± 1.97 4.39 ± 2.16 Time effect N.S
C 4.16 ± 1.56 4.13 ± 1.97 4.25 ± 1.88 4.40 ± 1.73
Intake at HA days I 7.17 ± 2.48 5.92 ± 3.10 5.93 ± 3.23 6.18 ± 3.65 Time effect p < 0.001
C 7.58 ± 3.11 6.35 ± 3.66 6.47 ± 3.20 6.00 ± 2.82
Intake
at migraine days		 I 5.27 ± 2.25 4.30 ± 2.76 4.83 ± 3.00 5.03 ± 3.52 Time effect p < 0.001
C 6.25 ± 2.98 5.04 ± 3.11 4.75 ± 2.82 5.02 ± 2.78
Calhoun
[31]
(2007)		 HA frequency
/28 days		 I 24.2 ** 17.4 **   p = 0.001 N ○ In I group, statistically significant reduction compared to C group observed headache frequency (p = 0.001) and Headache intensity(p= 0.01) at PT
○ No one in C group re-verted to episodic migraine, and 48.5% in I group reverted to epi-sodic migraine
C 23.2 ** 23.9 **  
HA Intensity I 46.7 ** 28.3 **   p = 0.01
C 50.2 ** 44.1 **  
Reverted to episodic migraine         p = 0.029
       
Scharff
[36]
(2002)		           PT F/U N ○ Clinical improvement in all variables (head-ache index change, highest intensity, days with headache) over time and compared with C group.
○ In HWB and HCB group
○ At PT, there is no significant temperature change
○ At 3 M F/U, temperature changes in both HWB and HCB group were significant com-pared to BL
○ At 6 M F/U, HWB group showed clinical improvement compared to HCB group
HA Index change (1) Effect of time
(Pillai’s trace = 0.267,
F[3, 29] = 3.53, p < 0.03)
(2) Trend for treatment group
(Pillai’s trace = 0.36,
F[6, 60] = 2.21, p < 0.05)		 (1) Effect for time
(Pillai’s trace =0.81,
F[9, 12] = 5.62, p < 0.01)
(2) Trend for treatment group
(Pillai’s trace = 0.32,
F[3, 18] = 2.80, p < 0.07)		 p < 0.005 p < 0.001
Highest intensity
rating for 2-week		 p < 0.01 N
HA days p < 0.02 p < 0.01
Temperature change (1) Effect of time
(Philai’s trace = 0.44,
F[12, 69] = 4.44, p < 0.001)
(2) No significant difference
in treatment		   6 M N
72.2% of HWB 20,
33.3% of HCB 21 were significant compared to BL
(χ² [1] = 3.76, p < 0.05).		 100% of HWB
62.5% of HCB
showed clinical improvement
(χ² [1] = 4.50, p < 0.05).
1 HDI: Headache Disability Inventory; 2 MIDAS: Migraine Disability Asessment; 3 MIDAS A: Self-reported headache days over a 90 day period, divided by 3; 4 MIDAS B: Self-reported average headache attack intensity over a 90 day period (1–10); 5 Average Attack Intensity/30 Days (by 1–3 scale); 6 MIDI = Migraine Disability Index (by 0–10 scale); 7 PSQI: Pittsburgh Sleep Quality Index; 8 ESS: Epworth Sleepiness Scale; 9 TST: Total Sleep Time; 10 PHQ-9: Patient Health Questionnaire 9-item Depression Module; 11 GAD-7: Generalized Anxiety Disorder 7-item Scale; 12 HIT-6: Headache Impact Test; 13 HADS: Hospital Anxiety and Depression Scale; 14 Brief-IPQ: Brief Illness Perceptions Questionnaire; 15 MSQoL: Migraine-Specific Quality of Life; 16 PHQ-9: Patient Health Questionnaire-depression module; 17 STAI: State Trait Anxiety Inventory; 18 PedMIDAS: The Pediatric Migraine Disability Assessment; 19 PedsQL: Pediatric Quality of Life Inventory (4th ed.); 20 HWB: handwarming biofeedback; 21 HCW: handcooling biofeedback; I, intervention; C, control; N.S., not statistically significant; BL, baseline; PT, post-treatment F/U, follow-up; M, months; Yrs, years; HA, headache; CBT, cognitive behavioral therapy; MCT, minimal contact therapy; Frequency of migraine, days per month during treatment; T, time effect.

References

  1. Olesen, J. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders third ed. Cephalalgia 2018, 38, 1–211.
  2. Vos, T.; Allen, C.; Arora, M.; Barber, R.M.; Bhutta, Z.A.; Brown, A.; Carter, A.; Casey, D.C.; Charlson, F.J.; Chen, A.Z.; et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016, 388, 1545–1602.
  3. Lipton, R.B.; Hutchinson, S.; Ailani, J.; Reed, M.L.; Fanning, K.M.; Adams, A.M.; Buse, D.C. Discontinuation of Acute Prescription Medication for Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache 2019, 59, 1762–1772.
  4. Van Den Brink, M.; Antoinette; MacGregor, E.A. Gender and Migraine; Springer International: Cham, Switzerland, 2019; pp. 1–15.
  5. Silberstein, S.D. Preventive migraine treatment. Contin. Lifelong Learn. Neurol. 2015, 21, 973–989.
  6. Goadsby, P.J.; Lipton, R.B.; Ferrari, M.D. Migraine—Current understanding and treatment. N. Engl. J. Med. 2002, 346, 257–270.
  7. Ashina, M.; Buse, D.C.; Ashina, H.; Pozo-Rosich, P.; Peres, M.F.P.; Lee, M.J.; Terwindt, G.M.; Singh, R.H.; Tassorelli, C.; Do, T.P.; et al. Migraine: Integrated approaches to clinical management and emerging treatments. Lancet 2021, 397, 1505–1518.
  8. Marmura, M.J.; Silberstein, S.D.; Schwedt, T.J. The acute treatment of migraine in adults: The American Headache Society evidence assessment of migraine pharmacotherapies. Headache 2015, 55, 3–20.
  9. Worthington, I.; Pringsheim, T.; Gawel, M.J.; Gladstone, J.; Cooper, P.; Dilli, E.; Aube, M.; Leroux, E.; Becker, W.J. Canadian Headache Society Guideline: Acute drug therapy for migraine headache. Can. J. Neurol. Sci. 2013, 40 (Suppl. 3), S1–S80.
  10. Evers, S.; Áfra, J.; Frese, A.; Goadsby, P.J.; Linde, M.; May, A.; Sándor, P.S. EFNS guideline on the drug treatment of migraine—Revised report of an EFNS task force. Eur. J. Neurol. 2009, 16, 968–981.
  11. Khan, J.; Al Asoom, L.I.; Al Sunni, A.; Rafique, N.; Latif, R.; Al Saif, S.; Almandil, N.B.; Almohazey, D.; AbdulAzeez, S.; Borgio, J.F. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed. Pharmacother. 2021, 139, 111557.
  12. Wells, R.E.; Burch, R.; Paulsen, R.H.; Wayne, P.M.; Houle, T.; Loder, E. Meditation for migraines: A pilot randomized controlled trial. Headache 2014, 54, 1484–1495.
  13. Jacobs, G.D. Clinical applications of the relaxation response and mind–body interventions. J. Altern. Complement. Med. 2001, 7 (Suppl. 1), S93–S101.
  14. Wells, R.E.; Smitherman, T.A.; Seng, E.K.; Houle, T.T.; Loder, E.W. Behavioral and mind/body interventions in headache: Unanswered questions and future research directions. Headache 2014, 54, 1107–1113.
  15. Wells, R.E.; Loder, E. Mind/Body and behavioral treatments: The evidence and approach. Headache 2012, 52 (Suppl. 2), 70–75.
  16. Peng, W.; Lauche, R.; Frawley, J.; Sibbritt, D.; Adams, J. Utilization of complementary and alternative medicine and conventional medicine for headache or migraine during pregnancy: A cross-sectional survey of 1835 pregnant women. Complement. Ther. Med. 2018, 41, 192–195.
  17. Thompson, D.F.; Saluja, H.S. Prophylaxis of migraine headaches with riboflavin: A systematic review. J. Clin. Pharm. Ther. 2017, 42, 394–403.
  18. Liampas, I.N.; Siokas, V.; Aloizou, A.-M.; Tsouris, Z.; Dastamani, M.; Aslanidou, P.; Brotis, A.; Dardiotis, E. Pyridoxine, folate and cobalamin for migraine: A systematic review. Acta Neurol. Scand. 2020, 142, 108–120.
  19. Liampas, I.; Siokas, V.; Brotis, A.; Dardiotis, E. Vitamin D serum levels in patients with migraine: A meta-analysis. Rev. Neurol. 2020, 176, 560–570.
  20. Hofmann, S.G.; Asnaani, A.; Vonk, I.J.J.; Sawyer, A.T.; Fang, A. The efficacy of cognitive behavioral therapy: A review of meta-analyses. Cogn. Ther. Res. 2012, 36, 427–440.
  21. Stewart, R.E.; Chambless, D.L. Cognitive–behavioral therapy for adult anxiety disorders in clinical practice: A meta-analysis of effectiveness studies. J. Consult. Clin. Psychol. 2009, 77, 595–606.
  22. Silberstein, S.D. Practice Parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55, 754–762.
  23. Sullivan, A.; Cousins, S.; Ridsdale, L. Psychological interventions for migraine: A systematic review. J. Neurol. 2016, 263, 2369–2377.
  24. Seng, E.K.; Singer, A.B.; Metts, C.; Grinberg, A.S.; Patel, Z.S.; Ma, M.M.; Ma, L.R.; Day, M.; Minen, M.T.; Lipton, R.B.; et al. Does mindfulness-based cognitive therapy for migraine reduce migraine-related disability in people with episodic and chronic migraine? A Phase 2b Pilot Randomized Clinical Trial. Headache 2019, 59, 1448–1467.
  25. Powers, S.W.; Kashikar-Zuck, S.M.; Allen, J.R.; LeCates, S.L.; Slater, S.K.; Zafar, M.; Kabbouche, M.A.; O’Brien, H.L.; Shenk, C.E.; Rausch, J.R.; et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: A randomized clinical trial. JAMA 2013, 310, 2622–2630.
  26. Grazzi, L.; Bernstein, C.; Raggi, A.; Sansone, E.; Grignani, E.; Searl, M.; Rizzoli, P. ACT for migraine: Effect of acceptance and commitment therapy (ACT) for high-frequency episodic migraine without aura: Preliminary data of a phase-II, multicentric, randomized, open-label study. Neurol. Sci. 2019, 40 (Suppl. 1), 191–192.
  27. Mansourishad, H.; Togha, M.; Borjali, A.; Karimi, R. Effectiveness of mindfulness-based cognitive-behavioral therapy on relieving migraine headaches. Arch. Neurosci. 2017, 4, e58028.
  28. Kosinski, M.; Bayliss, M.S.; Bjorner, J.B.; Ware, J.E., Jr.; Garber, W.H.; Batenhorst, A.; Cady, R.; Dahlöf, C.G.; Dowson, A.; Tepper, S. A six-item short-form survey for measuring headache impact: The HIT-6. Qual. Life Res. 2003, 12, 963–974.
  29. Rapoff, M.A.; Connelly, M.; Bickel, J.L.; Powers, S.W.; Hershey, A.D.; Allen, J.R.; Karlson, C.W.; Litzenburg, C.C.; Belmont, J.M. Headstrong intervention for pediatric migraine headache: A randomized clinical trial. J. Headache Pain 2014, 15, 12.
  30. Fritsche, G.; Frettlöh, J.; Hüppe, M.; Dlugaj, M.; Matatko, N.; Gaul, C.; Diener, H.-C. Prevention of medication overuse in patients with migraine. Pain 2010, 151, 404–413.
  31. Calhoun, A.H.; Ford, S. Behavioral sleep modification may revert transformed migraine to episodic migraine. Headache 2007, 47, 1178–1183.
  32. Ehde, D.M.; Dillworth, T.M.; Turner, J.A. Cognitive-behavioral therapy for individuals with chronic pain: Efficacy, innovations, and directions for research. Am. Psychol. 2014, 69, 153–166.
  33. Turner, J.A.; Holtzman, S.; Mancl, L. Mediators, moderators, and predictors of therapeutic change in cognitive–behavioral therapy for chronic pain. Pain 2007, 127, 276–286.
  34. Smitherman, T.A.; Walters, A.B.; Davis, R.E.; Ambrose, C.E.; Roland, M.; Houle, T.; Rains, J.C. Randomized controlled pilot trial of behavioral insomnia treatment for chronic migraine with comorbid insomnia. Headache 2016, 56, 276–291.
  35. Cousins, S.; Ridsdale, L.; Goldstein, L.H.; Noble, A.J.; Moorey, S.; Seed, P. A pilot study of cognitive behavioural therapy and relaxation for migraine headache: A randomised controlled trial. J. Neurol. 2015, 262, 2764–2772.
  36. Scharff, L.; Marcus, D.A.; Masek, B.J. A controlled study of minimal-contact thermal biofeedback treatment in children with migraine. J. Pediatr. Psychol. 2002, 27, 109–119.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Allergy
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Ji Yong Bae
View Times: 741
Revisions: 3 times (View History)
Update Date: 20 Jan 2022
Table of Contents
Academic Video Service
Feedback